ViaCell Obtains License to Oocyte Cryopreservation
By Biotechdaily staff writers
Posted on 29 Aug 2003
A worldwide license for the use of technology to cryopreserve unfertilized human oocytes has been obtained by ViaCell, Inc. (Boston, MA, USA) from Gamete Technology, Inc. (N. Kingston, RI, USA) and Massachusetts General Hospital (MGH, Boston, USA). Posted on 29 Aug 2003
The patented technology is designed to help freeze, store, and later fertilize oocytes for use in in vitro fertilization (IVF) around the world. The technology is the result of an eight-year development effort led by scientists at MGH. By freezing eggs before cancer treatment or earlier in life when egg quality is higher, a woman may be able to retain her ability to become pregnant and have a child many months or even years later. ViaCell also offers umbilical cord blood stem cell preservation services through a subsidiary called Viacord.
"This agreement with Gamete Technology positions ViaCell as a leader in the development of oocyte cryopreservation services, which has the clear potential to be one of the most significant advances in reproductive medicine since the introduction of IVF,” said Marc Beer, chairman and CEO of ViaCell.
Related Links:
ViaCell
Massachusetts General Hospital
New
Gold Member
Aspiration System
VACUSAFE
.jpg)
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
All-in-One Molecular System
AIO M160
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
